Are you looking for some ASX 200 shares for your self-managed superannuation fund (SMSF) this month?
If you are, it could be worth checking out the quality companies named below. They have all been tipped as buys with attractive upside. Here's what you need to know about them:
Image source: Getty Images
CSL Limited (ASX: CSL)
CSL could be a great option for a SMSF. It is one of the world's leading biotechnology companies that has been around for over a century, starting life as the Commonwealth Serum Laboratories.
It has stayed true to its roots since then with its key CSL Behring plasma business, whilst also expanding into other areas through its CSL Seqirus vaccines business and the CSL Vifor renal therapies business.
But CSL won't be stopping there. Each year it reinvests 10% to 12% of its sales back into research and development (R&D) activities. This ensures that it stays at the forefront of the industry and has a pipeline of potentially lucrative products to underpin its long term growth.
Analysts at Citi are positive on the company. They currently have a buy rating and $335.00 price target on its shares. Based on the current CSL share price, this implies potential upside of 10%.
Goodman Group (ASX: GMG)
Another ASX 200 share for SMSF investors to consider is Goodman Group. It is a leading integrated commercial and industrial property company.
It has been among the best performers on the Australian share market over the past decade. This has been driven by the insatiable demand for industrial property and management's strategy of developing high-quality properties in strategic locations.
Goodman appears well-placed to continue this positive form for the foreseeable future. This is thanks to its huge development pipeline, which includes data centres that are in demand due to the artificial intelligence megatrend.
Citi is also bullish on Goodman and has a buy rating and $40.00 price target on its shares. Based on its current share price of $34.58, this implies potential upside of almost 16%.
ResMed Inc. (ASX: RMD)
A third ASX 200 share to look at for your SMSF could be ResMed. It is a leading medical device company with a focus on the sleep disorder market.
This is a huge market to operate in. For example, last week its CEO, Mick Farrell stated that "nearly 2.5 billion suffer from major sleep health and breathing disorders."
And "as the market leader in these significantly underpenetrated markets, we're well-positioned as the clear leader to drive increased market penetration, demand generation, and accelerate growth for our businesses," Farrell added.
It's no wonder then that a number of brokers are bullish on ResMed. One of those is Macquarie, which has an outperform rating and $35.40 price target on its shares. This suggests that upside of over 11% is possible from current levels.
